135 related articles for article (PubMed ID: 21703936)
1. Prognostic significance of bone markers in patients with lung cancer metastatic to the skeleton: a review of published data.
Mountzios G; Ramfidis V; Terpos E; Syrigos KN
Clin Lung Cancer; 2011 Nov; 12(6):341-9. PubMed ID: 21703936
[TBL] [Abstract][Full Text] [Related]
2. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
Mountzios G; Dimopoulos MA; Bamias A; Papadopoulos G; Kastritis E; Syrigos K; Pavlakis G; Terpos E
Acta Oncol; 2007; 46(2):221-9. PubMed ID: 17453373
[TBL] [Abstract][Full Text] [Related]
3. Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid.
Mountzios G; Terpos E; Syrigos K; Papadimitriou C; Papadopoulos G; Bamias A; Mavrikakis M; Dimopoulos MA
Transl Res; 2010 May; 155(5):247-55. PubMed ID: 20403580
[TBL] [Abstract][Full Text] [Related]
4. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
[TBL] [Abstract][Full Text] [Related]
5. The clinical significance of serum markers of bone turnover in NSCLC patients: surveillance, management and prognostic implications.
Terpos E; Kiagia M; Karapanagiotou EM; Charpidou A; Dilana KD; Nasothimiou E; Harrington KJ; Polyzos A; Syrigos KN
Anticancer Res; 2009 May; 29(5):1651-7. PubMed ID: 19443381
[TBL] [Abstract][Full Text] [Related]
6. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS).
Politou M; Terpos E; Anagnostopoulos A; Szydlo R; Laffan M; Layton M; Apperley JF; Dimopoulos MA; Rahemtulla A
Br J Haematol; 2004 Sep; 126(5):686-9. PubMed ID: 15327520
[TBL] [Abstract][Full Text] [Related]
7. The changing landscape of the medical management of skeletal metastases in nonsmall cell lung cancer.
Kosteva J; Langer C
Curr Opin Oncol; 2008 Mar; 20(2):155-61. PubMed ID: 18300765
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.
Coleman RE; Major P; Lipton A; Brown JE; Lee KA; Smith M; Saad F; Zheng M; Hei YJ; Seaman J; Cook R
J Clin Oncol; 2005 Aug; 23(22):4925-35. PubMed ID: 15983391
[TBL] [Abstract][Full Text] [Related]
9. The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients.
Leeming DJ; Koizumi M; Byrjalsen I; Li B; Qvist P; Tankó LB
Cancer Epidemiol Biomarkers Prev; 2006 Jan; 15(1):32-8. PubMed ID: 16434583
[TBL] [Abstract][Full Text] [Related]
10. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
Koizumi M; Takahashi S; Ogata E
Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607
[TBL] [Abstract][Full Text] [Related]
11. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid.
Pectasides D; Nikolaou M; Farmakis D; Kanakis I; Gaglia A; Kountourakis P; Karamanos NK; Economopoulos T; Raptis SA
Anticancer Res; 2005; 25(2B):1457-63. PubMed ID: 15865105
[TBL] [Abstract][Full Text] [Related]
12. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications.
Jung K; Lein M; Stephan C; Von Hösslin K; Semjonow A; Sinha P; Loening SA; Schnorr D
Int J Cancer; 2004 Sep; 111(5):783-91. PubMed ID: 15252851
[TBL] [Abstract][Full Text] [Related]
13. The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load.
Generali D; Berruti A; Tampellini M; Dovio A; Tedoldi S; Bonardi S; Tucci M; Allevi G; Aguggini S; Milani M; Bottini A; Dogliotti L; Angeli A
Bone; 2007 Jan; 40(1):182-8. PubMed ID: 16935041
[TBL] [Abstract][Full Text] [Related]
14. Biochemical picture of bone metabolism in breast cancer patients with bone metastases.
Berruti A; Torta M; Piovesan A; Raucci CA; Orlandi F; Panero A; Dogliotti L; Angeli A
Anticancer Res; 1995; 15(6B):2871-5. PubMed ID: 8669881
[TBL] [Abstract][Full Text] [Related]
15. [Bone turnover markers in the detection of bone metastases in primary lung cancer].
Kong QQ; Tu CQ; Dou QY; Wang JP; Sun TW
Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 May; 36(3):397-9. PubMed ID: 15931879
[TBL] [Abstract][Full Text] [Related]
16. Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease.
Saad F; Lipton A
Semin Oncol; 2007 Dec; 34(6 Suppl 4):S17-23. PubMed ID: 18068486
[TBL] [Abstract][Full Text] [Related]
17. Receptor activator of NF(Kappa)B ligand/osteoprotegerin (RANKL/OPG) system and osteopontin (OPN) serum levels in a population of apulian postmenopausal women.
D'Amore M; Fanelli M; D'Amore S; Fontana A; Minenna G
Panminerva Med; 2006 Dec; 48(4):215-21. PubMed ID: 17215793
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease.
Tucci M; Mosca A; Lamanna G; Porpiglia F; Terzolo M; Vana F; Cracco C; Russo L; Gorzegno G; Tampellini M; Torta M; Reimondo G; Poggio M; Scarpa RM; Angeli A; Dogliotti L; Berruti A
Prostate Cancer Prostatic Dis; 2009; 12(1):94-9. PubMed ID: 18332901
[TBL] [Abstract][Full Text] [Related]
19. Serum N-telopeptide of type I collagen and bone alkaline phosphatase and their relationship in patients with non-small cell lung carcinoma and bone metastases. Preliminary results.
Lumachi F; Marino F; Fanti G; Chiara GB; Basso SM
Anticancer Res; 2011 Nov; 31(11):3879-81. PubMed ID: 22110213
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic and prognostic use of bone turnover markers.
Joerger M; Huober J
Recent Results Cancer Res; 2012; 192():197-223. PubMed ID: 22307377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
